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Background: The Wnt/β-catenin/T cell factor (TCF) signaling pathway is important in the 
development of nonmelanoma skin cancers (NMSCs). Nitric-oxide-releasing nonsteroidal anti-
inflammatory drugs (NO-NSAIDs) are chemopreventive agents consisting of a traditional NSAID 
attached to an NO-releasing moiety through a chemical spacer. Previously we showed that an 
aromatic spacer enhanced the potency of a particular NO-NSAID compared to an aliphatic spacer.
Methods: We synthesized an NO-releasing NSAID with an aromatic spacer (flurbiprofen benzyl 
nitrate, NBS-242), and using the human skin cancer cell line A-431, we evaluated its effects on 
cell kinetics, Wnt/β-catenin, cyclin D1, and caspase-3.
Results: NBS-242 inhibited the growth of A-431 cancer cells, being ∼15-fold more potent than 
flurbiprofen and up to 5-fold more potent than NO-flurbiprofen with an aliphatic spacer, the half 
maximal inhibitory concentrations (IC
50
) for growth inhibition being 60 ± 4 µM, 320 ± 20 µM, 
and 880 ± 65 µM for NBS-242, NO-flurbiprofen, and flurbiprofen, respectively. This effect 
was associated with inhibition of proliferation, accumulation of cells in the G
0
/G
1
 phase of the 
cell cycle, and an increase in apoptotic cell population. NBS-242 cleaved β-catenin both in 
the cytoplasm and the nucleus of A-431 cells. NBS-242 activated caspase-3 whose activation 
was reflected in the cleavage of procaspase-3. To test the functional consequence of β-catenin 
cleavage, we determined the expression of cyclin D1, a Wnt-response gene. NBS-242 reduced 
cyclin D1 levels in a concentration dependent manner.
Conclusion: These findings establish a strong inhibitory effect of NBS-242 in A-431 human 
epidermoid carcinoma cells. NBS-242 modulates parameters that are important in determining 
cellular mass.
Keywords: flurbiprofen, nitric oxide, β-catenin, chemoprevention, skin cancer
Introduction
In the USA, nonmelanoma skin cancers (NMSCs) are increasing by about one million 
new cases annually.1 The Wnt/β-catenin/T cell factor (TCF) signaling pathway has 
been shown to be important in the development of many cancers including colon, 
prostate, leukemia, and others. The Wnt/β-catenin pathways are also implicated in the 
development of malignancy in NMSCs such as squamous cell carcinoma (SCC) of the 
skin2,3 and basal cell carcinoma (BCC).4 Mouse models of induced skin tumors have 
provided evidence of constitutive activation of β-catenin/TCF signaling.5 β-catenin is a 
multifunctional protein that controls a number of cell activities, both at the membrane 
and the nuclear level. In the nucleus, β-catenin interacts with the TCF family of 
transcription factors. Elevated β-catenin/TCF-4 signaling is correlated with activation 
of its downstream target cyclin D1 and accelerated entry from the G
1
 phase into the 
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S phase of the cell cycle. The upregulation of cyclin D1 is 
generally accepted as the basis for β-catenin’s proliferative 
and oncogenic effect.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
considered to be the prototypical cancer chemopreventive 
agents.6 A number of randomized, double-blind trials 
of aspirin against colorectal adenomas have established 
their chemopreventive effect.7–9 Recently, Rothwell et al10 
reported that even daily use of low dose aspirin resulted in 
reductions in cancer incidence and mortality. Moreover, 
they also reported that aspirin prevented distant metastasis.11 
For skin cancer, NSAIDs have been shown to have a 
protective effect against SCC and BCC.12 Interestingly, 
the data suggested that a shorter duration of use offered 
a better protective effect than a longer duration of use. 
Recently, it was shown that celecoxib, an NSAID which 
selectively inhibits the enzyme cyclo-oxygenase-2, may be 
effective for prevention of SCCs and BCCs in individuals 
who have extensive actinic damage and are at high risk 
for development of nonmelanoma skin cancers.13 A recent 
study concluded that long-term use (.5 years) of NSAIDs, 
especially aspirin, was associated with a significantly 
decreased risk of developing cutaneous melanoma.14 
However, regular NSAID use may lead to serious side 
effects encompassing the gastrointestinal, renal, and 
cardiovascular systems.15–17 These potential life-threatening 
side effects are limiting to the widespread use of NSAIDs 
as potential chemopreventive agents.
Nitric-oxide-releasing NSAIDs (NO-NSAIDs) are 
an emerging new class of chemopreventive agents. They 
consist of a traditional NSAID attached to an NO-releasing 
moiety through a chemical spacer. Animal18,19 and human20,21 
studies have shown that many NO-NSAIDs are safer to the 
gastrointestinal mucosa than the parent NSAID. We had 
previously shown that an aromatic spacer enhanced the potency 
of a particular NO-NSAID compared to an aliphatic spacer.22 
At the cellular level, our previous studies have also demonstrated 
that the chemopreventive effects may be mediated through 
proapoptotic and antiproliferative effects of NO-NSAIDs in 
various cancer cell lines of different cell types.23,24 Hence, for 
these studies, we synthesized an NO-releasing arylpropionic 
acid NSAID, comprising an aromatic spacer and evaluated it 
against the human skin cancer cell line, A-431 which expresses 
β-catenin. In this study, we compared the effects of the NSAID 
flurbiprofen, NO-releasing-flurbiprofen containing an aliphatic 
spacer, and the newly synthesized flurbiprofen benzyl nitrate 
(FBN, NBS-242), which has an aromatic spacer on cell growth 
inhibition. The effect of FBN on cell proliferation, apoptosis, 
and cell cycle was examined with a focus on the Wnt pathway 
components.
Materials and methods
Reagents and cell culture
NO-flurbiprofen (4-(nitrooxy)butyl 2-(2-fluoro-[1,1′-
biphenyl]-4-yl)propanoate) and flurbiprofen benzyl 
nitrate (4-O-[2-(3-fluoro-4-phenyl)phenyl propionyl]-
4-hydroxybenzyl nitrate, NBS-242) (Figure 1) were 
synthesized and purified as described previously.25 Stock 
solutions (100 mM) were made in dimethyl sulfoxide 
(DMSO); the final DMSO concentration was adjusted in all 
media to 1%. Flurbiprofen and other fine chemicals were 
obtained from Sigma-Aldrich (St Louis, MO, USA). A-431 
human epidermoid carcinoma (ATCC, Manassas, VA, USA) 
cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 
100 unit/mL of penicillin, and 100 µg/mL of streptomycin 
in a humidified atmosphere containing 5% CO
2
 and 95% 
air at 37°C.
Determination of cell viability 
by MTT assay
Cell growth inhibition was measured using an MTT kit 
(Roche, Indianapolis, IN, USA). A-431 cells were plated 
at a density of 7000 cells/well in a 96-well plate. After 
overnight incubation, cells were treated with vehicle or 
various concentrations of the test compounds for 24 hours 
after which viable cells were quantified according to the 
Traditional NSAID
Flurbiprofen benzyl nitrate
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Figure 1 Structural features of flurbiprofen, NO-flurbiprofen, and flurbiprofen 
benzyl nitrate.
Abbreviations: NO, nitric oxide; NSAID, nonsteroidal anti-inflammatory drug.
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manufacturer’s instructions. Growth inhibition was expressed 
as percentage of the corresponding control.
Proliferating cell nuclear antigen (PCNA) 
staining for cell proliferation
A-431 cells (8000 cells/well) were treated for 24 hours 
with various concentrations of FBN. Cell proliferation was 
assessed by measuring the levels of PCNA using a PCNA 
enzyme-linked immunosorbent assay kit (Calbiochem, La 
Jolla, CA, USA), in accordance with the manufacturer’s 
protocol.
4,6-diamidino-2-phenylindole (DAPI) 
staining for cell death analysis
Chromatin condensation for detection of apoptosis was 
determined by DAPI fluorescence. Cells were cultured in 
the growth medium in the presence or absence of FBN for 
24 hours. Cells were washed three times with phosphate-
buffered solution (PBS), fixed in a 3.7% formaldehyde 
solution for 10 minutes, fixed once in 1 mL of methanol, 
stained, and mounted in a fluid containing 2 mg/mL 
DAPI (Oncor Inc, Gaithersburg, MD, USA). Results were 
determined by visual observation of nuclear morphology via 
fluorescence microscopy.
Cell cycle analysis
A-431 cells were treated for 24 hours with various concentrations 
of FBN. Cell cycle phase distributions of control and treated 
cells were obtained using a Coulter Profile XL, (Beckman 
Coulter, Inc., Fullerton, CA, USA) equipped with a single 
argon ion laser. For each subset, .10,000 events were 
analyzed. All parameters were collected in list mode files. Data 
were analyzed on a Coulter XL Elite Workstation, (Beckman 
Coulter, Inc.) using the software programs Multigraph and 
Multicycle. Cells (0.5 × 106) were fixed in 100% methanol 
for 10 minutes at −20°C, pelleted (5000 rpm for 10 minutes 
at 4°C), resuspended, and incubated in PBS containing 1% 
FBS/0.5% NP-40 on ice for 5 minutes. Cells were washed 
again in 500 µL of PBS/1% FBS containing 40 µg/mL 
propidium iodide (used to stain for DNA) and 200 µg/mL 
RNase type IIA, and analyzed within 30 minutes by flow 
cytometry. The percentage of cells in the G
0
/G
1
, G
2
/M, and S 
phases was determined from DNA content histograms.
Cytoplasmic and nuclear protein 
extraction
To obtain nuclear protein extracts, cell pellets were resuspended 
in 500-µL lysis-buffer I (10 mM Tris-HCl [ph 7.4], 10 mM 
NaCl, 3 mM MgCl
2
, and 0.5% NP-40), incubated for 5 minutes 
on ice, and centrifuged at 3200 rpm for 5 minutes. Nuclei were 
then washed with washing buffer (10 mM Tris-HCl [pH 7.4], 
10 mM NaCl, and 3 mM MgCl
2
), resuspended in lysis-buffer 
II (20 mM Tris-HCl [pH 7.4], 40 mM Na-pyrophosphate, 
50 mM NaF, 5 mM MgCl
2
, 20 mM ethylenediaminetetraacetic 
acid [EDTA], 1% Triton-X-100, and 0.5% SDS, 0.1 mM 
phenylmethylsulfonyl fluoride [PMSF]), sonicated, and 
centrifuged at 14,000 rpm for 10 minutes. The supernatant 
was diluted by the addition of one vol lysis buffer III (20 mM 
HEPES-KOH, pH 7.4, 0.2 mM EDTA, 0.5 mM PMSF, and 
2 mM dithiothreitol). Glycerol was added to obtain a final 
concentration of 20%, and aliquots were stored at −80°C. 
Lastly, 50 µg of soluble extracts and 30 µg of nuclear extracts 
were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by immunoblotting 
according to standard protocols.
Antibodies
Primary mouse monoclonal antibodies were against the following 
at the dilutions indicated: β-catenin, 1:1000 (BD Transduction 
Laboratories, San Jose, CA, USA); TCF-4, 1:500 (Upstate 
Biotechnology, Lake Placid, NY, USA); α-tubulin, 1:1000 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); Cox-2, 
1:2000 (Cayman Chemicals, Ann Arbor, MI, USA), and rabbit 
polyclonal anti-cyclin D1, 1:1000 (Upstate Biotechnology). 
Secondary antibodies conjugated to horseradish peroxidase 
(1:4000) were from Sigma-Aldrich. Immunoreactive protein 
was detected by using chemiluminescence (Pierce Chemicals, 
Rockford, IL, USA).
Statistics
Data are presented as the mean ± standard error of the mean, 
with sample sizes as indicated in figure legends. Comparisons 
between groups were performed using a one-way analysis 
of variance followed by a Student’s t-test; P , 0.05 was 
considered significant.
Results
FBN strongly inhibits the growth 
of A-431 cells
We examined the growth inhibitory activities of FBN, 
NO-flurbiprofen, and flurbiprofen (their structures are 
presented in Figure 1) by an MTT assay in the A-431 human 
epidermoid carcinoma cell line. For the initial growth 
inhibition study, a wide range of doses of the three compounds, 
including up to 1000 µM for flurbiprofen, were used in 
order to obtain observable readouts for all the compounds. 
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After treatment of cells for 24 hours, the percent inhibition 
was determined for the various concentrations examined. 
Overall, all three compounds inhibited cell growth in 
a concentration-dependent manner. Among the three 
compounds, flurbiprofen exhibited a moderate inhibitory 
effect on cell growth, the aliphatic NO-flurbiprofen strongly 
inhibited growth, whereas the aromatic NO-flurbiprofen 
(FBN) was significantly more potent (Figure 2). The half 
maximal inhibitory concentration (IC
50
) values determined 
for each compound were 880 ± 65 µM, 320 ± 20 µM, and 
60 ± 4 µM for flurbiprofen, aliphatic NO-flurbiprofen, and 
FBN, respectively. The ratio of the IC
50
s (traditional NSAID/
modified NSAID), which reflects the fold increase in potency, 
indicated that FBN was 15-fold more potent than flurbiprofen 
and up to 5-fold more potent than NO-flurbiprofen. A lower 
IC
50
 of FBN compared to NO-flurbiprofen in A-431 cells 
strongly suggests that the aromatic spacer may contribute 
to the strong growth suppressive properties of FBN either 
alone or by modifying delivery of NO. For further studies 
we focused on the effects of FBN on cellular kinetics such 
as proliferation, apoptosis, and cell cycle.
FBN affects proliferation 
and induces apoptosis
Proliferation and apoptosis are two major parameters 
determining cellular mass. We examined the effects of FBN 
after 24 hours of treatment on these two parameters. PCNA 
is an index of the proliferative status of cells. FBN caused a 
concentration-dependent reduction of PCNA in A-431 cells 
from 10 to 75 µM (Figure 3A). Compared to the control, 
the maximal antiproliferative activity of FBN was 15% 
at 75 µM and remained relatively constant for increasing 
concentrations, suggesting that inhibition of proliferation 
may be a partial contributor to the growth inhibitory effect 
of FBN. On the other hand, the percentage of apoptotic cells, 
as measured by counting DAPI stained nuclei with apoptotic 
morphology, increased in a concentration dependent 
manner from 10 to 100 µM FBN. At 75 µM, approximately 
50% of the cells were apoptotic compared to the control 
(Figure 3A).
Since the induction of apoptosis may be mediated through 
the regulation of cell cycle, we examined the effect of FBN 
on cell cycle perturbations (Figure 3B). Cells were treated 
with various concentrations of FBN for 24 hours and their 
DNA content, as assessed by flow cytometric analysis, 
indicated that FBN-treated cells progressively accumulated 
in the G
0
/G
1
 phase; for example, at 100 µM compared to 
untreated cells, the proportion of cells in the G
0
/G
1
 phase 
increased from 61% to 73%, and concomitantly decreased 
the proportion of cells in the G
2
/M phase from 21% to 9%. 
Collectively, our data indicate that FBN induces cell cycle 
arrest and apoptosis in A-431 cells.
FBN targets components of the Wnt 
pathway and induces caspase-3
According to the canonical Wnt/β-catenin pathway, β-catenin 
translocates to the nucleus, interacting with TCF and 
modulating transcription of specific genes. We examined the 
effect of FBN on β-catenin protein levels in the cytoplasm 
and nucleus in these cells. FBN cleaved cytoplasmic and 
nuclear β-catenin as a function of concentration (Figure 4A 
and B), with substantial degradation at 75 µM and 100 µM. 
In the cytoplasm, the functional consequence of reduced 
levels of β-catenin cleavage was examined by determining 
the cytoplasmic protein expression of cyclin D1. Cyclin D1 
represents an early G
1
 phase cyclin and is a consequence 
of β-catenin/TCF-4 transcriptional activity. FBN at 25 µM 
reduced cytoplasmic cyclin D1 levels and abrogated its 
expression completely at 75 µM (Figure 4A). This abrogation 
was associated with β-catenin degradation observed at these 
concentrations. On the other hand, nuclear expression of cyclin 
D1, which is a result of protein export from the cytoplasm to 
the nucleus, was also strongly reduced (Figure 4B). Since these 
cells were asynchronously dividing, it is understandable that at 
FBN (NBS-242)
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Figure 2 Inhibitory effect of FBN on A-431 cell growth.
Notes: Cells were treated with increasing concentrations of flurbiprofen, NO 
flurbiprofen, and FBN for 24 hours. Cell viability was determined by MTT assay as 
described in the Materials and methods section. Results are means ± SEM of three 
different experiments performed in triplicate. *P , 0.05 compared to flurbiprofen; 
†P , 0.01 compared to flurbiprofen; §P , 0.05 compared to NO-flurbiprofen.
Abbreviations: FBN, flurbiprofen benzyl nitrate; IC50, half maximal inhibitory 
concentration; NO, nitric oxide; NSAID, nonsteroidal anti-inflammatory drug; 
SEM, standard error of the mean.
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any time of treatment with FBN cytoplasmic cyclin D1 and its 
nuclear levels will be affected. We further examined the protein 
level of TCF-4, the transcription factor in the nucleus that binds 
to β-catenin. FBN completely reduced the expression of TCF-4 
at 75 µM. Thus, FBN targets the two major elements of the Wnt 
pathway, namely β-catenin and TCF-4. Our data demonstrate 
that FBN induces G
1
 cell cycle arrest, which agrees well with 
the marked downregulation of cyclin D1.
We also examined the activation of caspases by 
FBN since there was a strong induction of apoptosis in 
A-431 cells by DAPI staining as shown in Figure 3A. 
Caspase activation constitutes the hallmark of apoptotic 
detection and it is well known that β-catenin is a direct 
target of caspase-3 activity.24 Therefore, the activation 
of caspase-3 was examined in the cytoplasm fraction of 
A-431 cells by performing immunoblotting detection for 
procaspase-3 and its smaller cleaved fragment, signifying 
the activation of caspase-3. The appearance of activated 
caspase-3 was observed initially at 50 µM FBN, followed 
by a substantial increase in activation at 75 and 100 µM 
FBN, with simultaneous reduction in levels of procaspase-3 
(Figure 4A). The activation of caspase-3 coincided with the 
cleavage of β-catenin at 50 and 75 µM suggesting that there 
is an association between the events.
Discussion
This study demonstrates the potential of the aromatic 
NO-releasing compound FBN against skin cancer of the 
nonmelanocytic type that is known to occur via constitutive 
activation of β-catenin/TCF signaling. We report, for the first 
time, the effects of an NO-releasing flurbiprofen that has an 
aromatic spacer. FBN is more potent than NO-flurbiprofen 
and flurbiprofen in inhibiting the growth of the A-431 skin 
cancer cell line.
The data suggest a possible link between the growth 
inhibitory effects of FBN and the β-catenin pathway as a 
potential target. Studies in recent years have suggested that 
β-catenin accumulation has been implicated in tumorigenesis 
in a wide variety of human cancers including skin cancer.3 
These studies suggest, in essence, that degrading nuclear 
accumulation of β-catenin suppresses tumorigenesis. Our data 
show the possible molecular mechanism underlying the anti-
growth effect of FBN. Taken together, these results suggest that 
the reduction of β-catenin expression by FBN may contribute 
to an antiproliferative mechanism in A-431 skin cancer 
cells. Others have shown that downregulation of β-catenin 
expression by accelerating its proteasomal degradation led 
to impaired cell proliferation and abolished the tumorigenic 
potential of these cells in the nude mice model.26 In this 
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Figure 3 Effect of FBN on cell kinetics. FBN causes G0/G1 cell cycle arrest, induces apoptosis, and inhibits proliferation. (A) A-431 cells were treated with FBN at the 
indicated concentrations for 24 hours followed by PCNA quantification for proliferation or DAPI staining of apoptotic nuclei and counting as described in the Materials and 
methods section. Results are mean ± SEM of three different experiments. *P , 0.05; †P , 0.01 compared with untreated cells. (B) Asynchronous A-431 cells were treated 
with increasing concentrations of FBN as indicated for 24 hours.
Notes: The cells were then harvested and the percentage of the cells in the G0/G1, S, and G2/M phases were analyzed by flow cytometry. The populations of the cells (G0/G1, 
S, and G2/M phases) are expressed as a percentage of the total cell population. Data shown here are from a representative experiment repeated two times with similar 
results, within 10% of each other.
Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; FBN, flurbiprofen benzyl nitrate; PCNA, proliferating cell nuclear antigen; SEM, standard error of the mean.
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regard, the NSAID R-flurbiprofen was reported to show strong 
antiproliferative effects in vivo and in vitro.27 However, very 
high concentrations of this compound, such as 1000 µM 
R-flurbiprofen, did not affect the protein level of β-catenin or 
induce its degradation.27 An interesting future goal would be to 
determine whether proteolytic cleavage of β-catenin is simply 
an effect of apoptosis or induces the apoptotic program. The 
versatile functions of β-catenin within the interplay of cell 
growth and cell death will be an interesting aspect for future 
studies on FBN.
Since the only difference between NO-flurbiprofen and 
FBN is the linker joining the NO-releasing group to the 
NSAID flurbiprofen, it may be concluded that the enhanced 
potency observed with FBN may be due to the aromatic linker 
alone, or the way in which NO is delivered or a combination 
of both.
Previous work by us on the structure–activity properties of 
NO-aspirin had indicated that NO was pivotal for its anticancer 
effects.22 However, careful re-examination regarding the 
contribution to the overall biological effect of each of the 
three structural components of NO- acetylsalicylate (ASA) 
in which the spacer joining the ASA to the NO-releasing 
moiety was aromatic, led us and others to conclude that 
the NO-releasing moiety was not required for the observed 
biological effects. Rather, the spacer was responsible for 
the biological actions of NO-aspirin, with the NO-releasing 
moiety acting as a leaving group that facilitated the release 
and activation of the spacer to a quinone methide intermediate 
which acted as a powerful electrophile.28–30 Here, we have 
NO-flurbiprofen which was ∼2.8-fold more potent than its 
parent compound flurbiprofen in inhibiting the growth of 
A-431 cells and FBN which was ∼15-fold more potent. On 
this basis, we may cautiously conclude that with FBN we may 
have two effects, one as a result of released NO and one due 
to an active aromatic linker.
Finally, FBN is able to reduce PCNA levels, which is 
a polymerase accessory protein detected in a cell-cycle-
dependent manner,31 with a marked downregulation of cyclin 
D1. The cyclin D1 proto-oncogene is an important regulator 
of G
1
 to S phase transition in numerous cell types from diverse 
tissues. This series of events results in a G
1
 phase arrest of 
the cell cycle, which is an irreversible process that ultimately 
results in the apoptotic death of cancer cells.
In conclusion our data establish a strong inhibitory 
effect of FBN in A-431 human epidermoid carcinoma cells, 
an effect that is modulated through parameters important 
in determining cellular mass. FBN is more potent than 
NO-flurbiprofen and flurbiprofen in the inhibition of cell 
proliferation. Activation of caspase-3 is associated with 
degradation of β-catenin and reduction in cyclin D1 levels, 
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Figure 4 FBN degrades β-catenin, inhibits cyclin D1, and activates caspase-3.
Notes: A-431 cells were treated with FBN at the indicated concentrations for 24 hours followed by cytoplasmic and nuclear protein extraction. Proteins were detected by 
immunoblotting with specific antibodies. Results are representative of two independent experiments. The densitometry of the bands was within 15% of each other.
Abbreviations: FBN, flurbiprofen benzyl nitrate; TCF, T-cell factor.
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suggesting that FBN has potential as a chemotherapeutic 
agent against NMSC.
Two major aspects constitute future directions for this study. 
First, at the mechanistic level, the degradation of β-catenin by 
FBN merits further investigation regarding the sequence of events 
in relation to caspase activity. A second focus is the potential 
of FBN in topical treatment regimens, which are generally 
considered to be better alternatives for nonmelanoma skin 
cancer in minimizing systemic exposure while achieving high 
local concentrations of the drug. We are currently formulating 
hydrogel-delivering systems for local application of FBN.
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